Ralliant (NYSE:RAL) Upgraded to Strong-Buy at Zacks Research

Ralliant (NYSE:RAL) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

RAL has been the subject of several other reports. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Royal Bank Of Canada boosted their target price on Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Wednesday, May 13th. Morgan Stanley upped their target price on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Wall Street Zen cut Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Oppenheimer boosted their price objective on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $69.00.

Ralliant Stock Down 2.3%

NYSE RAL opened at $71.93 on Tuesday. Ralliant has a 12 month low of $37.27 and a 12 month high of $75.41. The company has a market capitalization of $8.05 billion and a P/E ratio of -6.57. The company’s 50 day simple moving average is $59.71 and its 200 day simple moving average is $51.69. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05.

Ralliant (NYSE:RAL) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts expect that Ralliant will post 2.64 earnings per share for the current fiscal year.

Institutional Trading of Ralliant

Several hedge funds and other institutional investors have recently modified their holdings of the business. Dodge & Cox boosted its position in Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after acquiring an additional 1,434,376 shares during the period. Viking Global Investors LP purchased a new stake in shares of Ralliant in the second quarter worth approximately $257,200,000. Millennium Management LLC lifted its position in shares of Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after purchasing an additional 3,147,660 shares in the last quarter. State Street Corp acquired a new stake in shares of Ralliant during the second quarter worth approximately $213,096,000. Finally, Invesco Ltd. grew its position in Ralliant by 4.9% during the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock valued at $206,674,000 after purchasing an additional 187,898 shares in the last quarter.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.